Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 25
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 21 more

Conditions: Kidney Transplantation
Interventions: Mycophenolate mofetil, Cyclosporine, Tacrolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more

Conditions: Urinary Tract Infections
Interventions: Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 1,531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
Interventions: Promacta, blood drawing in patients with WAS, blood drawing in healthy controls; Drug · Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 3 Months to 80 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma, Obesity
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Colchester, Vermont

Conditions: Acute Uncomplicated Diverticulitis
Interventions: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, Placebo, Metronidazole, Cefuroxime; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Hepatitis C Virus Infection
Interventions: telaprevir, VX-222, ribavirin, peginterferon-alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 16 more

Conditions: Epilepsy
Interventions: Perampanel Oral Tablet; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Heart Failure
Interventions: Empagliflozin 10 mg Tab, Placebo Oral Tablet; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 19 Years to 119 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Los Angeles, California • Jacksonville, Florida • Evanston, Illinois + 7 more

Conditions: Hepatitis C
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 47
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more

Conditions: Hypogonadism, Diabetes, Sarcopenia, Osteoporosis, Depression
Interventions: Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Placebo tablet, Placebo gel, Calcium Cardone 500mg with vitamin D 400 IU; Drug · Dietary Supplement
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Adult Participants
Interventions: PF-07248144, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cervical Dystonia
Interventions: Perampanel; Drug
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more

Conditions: Metastatic Colorectal Cancer
Interventions: Precemtabart tocentecan, Bevacizumab, Trifluridine/Tipiracil (FTD-TPI); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 22
States / cities: San Francisco, California • Lone Tree, Colorado • Fort Myers, Florida + 19 more

Conditions: Acute Myeloid Leukemia, AML, Childhood
Interventions: Cytarabine, Daunorubicin, Erwinase, Etoposide, Gemtuzumab ozogamicin, Stem cell transplantation (SCT), Sorafenib; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Divorce
Interventions: Online New Beginnings Program (eNBP); Behavioral
Lead sponsor: Family Transitions: Programs that Work; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Heart Failure
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 39 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more

Conditions: Breast Cancer, Breast Carcinoma, Breast Tumors
Interventions: Letrozole, palbociclib; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Long Beach, California • Miami, Florida • Decatur, Illinois + 13 more

Conditions: Clinical Pharmacology
Interventions: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Proliferative Diabetic Retinopathy
Interventions: emixustat hydrochloride, Placebo; Drug · Other
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: PH-797804, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 22
States / cities: Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more

Conditions: Pain
Interventions: Hydrocodone/Acetaminophen Extended Release, Acetaminophen, Morphine Extended Release, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Peoria, Arizona • Austin, Texas • San Marcos, Texas + 1 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Cabozantinib (XL184); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Search by objective public record fields.

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Fycompa Titration Intervals and Effects on Retention Rate

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)

Safety and Tolerability of Perampanel in Cervical Dystonia

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

AflacLL1901 (CHOA-AML)

An Internet Based Adaptation of a Divorce Intervention Beginnings Program for Divorced Parents

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma